Georgopoulou, Dimitra
Callari, Maurizio
Rueda, Oscar M. http://orcid.org/0000-0003-0008-4884
Shea, Abigail
Martin, Alistair
Giovannetti, Agnese http://orcid.org/0000-0001-5207-7243
Qosaj, Fatime
Dariush, Ali
Chin, Suet-Feung http://orcid.org/0000-0001-5697-1082
Carnevalli, Larissa S. http://orcid.org/0000-0001-7432-0195
Provenzano, Elena http://orcid.org/0000-0003-3345-3965
Greenwood, Wendy
Lerda, Giulia
Esmaeilishirazifard, Elham
O’Reilly, Martin
Serra, Violeta http://orcid.org/0000-0001-6620-1065
Bressan, Dario http://orcid.org/0000-0003-3592-699X
Ali, H. R.
Al Sa’d, M.
Alon, S.
Aparicio, S.
Battistoni, G.
Balasubramanian, S.
Becker, R.
Bodenmiller, B.
Boyden, E. S.
Bressan, D.
Bruna, A.
Burger, Marcel
Caldas, C.
Callari, M.
Cannell, I. G.
Casbolt, H.
Chornay, N.
Cui, Y.
Dariush, A.
Dinh, K.
Emenari, A.
Eyal-Lubling, Y.
Fan, J.
Fatemi, A.
Fisher, E.
González-Solares, E. A.
González-Fernández, C.
Goodwin, D.
Greenwood, W.
Grimaldi, F.
Hannon, G. J.
Harris, O.
Harris, S.
Jauset, C.
Joyce, J. A.
Karagiannis, E. D.
Kovačević, T.
Kuett, L.
Kunes, R.
Küpcü, Yoldaş A.
Lai, D.
Laks, E.
Lee, H.
Lee, M.
Lerda, G.
Li, Y.
McPherson, A.
Millar, N.
Mulvey, C. M.
Nugent, F.
O’Flanagan, C. H.
Paez-Ribes, M.
Pearsall, I.
Qosaj, F.
Roth, A. J.
Rueda, O. M.
Ruiz, T.
Sawicka, K.
Sepúlveda, L. A.
Shah, S. P.
Shea, A.
Sinha, A.
Smith, A.
Tavaré, S.
Tietscher, S.
Vázquez-García, I.
Vogl, S. L.
Walton, N. A.
Wassie, A. T.
Watson, S. S.
Weselak, J.
Wild, S. A.
Williams, E.
Windhager, J.
Whitmarsh, T.
Xia, C.
Zheng, P.
Zhuang, X.
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Ali, H. Raza http://orcid.org/0000-0001-7587-0906
Cosulich, Sabina S.
Hannon, Gregory J.
Bruna, Alejandra
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
,
Funding for this research was provided by:
Cancer Research UK
EC | Horizon 2020 Framework Programme (ERC-2015-AdG-694620, 660060)
AstraZeneca
Article History
Received: 28 August 2020
Accepted: 26 February 2021
First Online: 31 March 2021
Competing interests
: C.C. is a member of AstraZeneca’s iMED External Science Panel, of Illumina’s Scientific Advisory Board, and is a recipient of research grants (administered by the University of Cambridge) from AstraZeneca, Genentech, Roche, and Servier. L.S.C. and S.S.C. are employees and shareholders of AstraZeneca. V.S. received research support from AstraZeneca, Novartis, Genentech and Tesaro. The remaining authors declare no competing interests.